Conduit Pharmaceuticals Inc. (CDT)
Automate Your Wheel Strategy on CDT
With Tiblio's Option Bot, you can configure your own wheel strategy including CDT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CDT
- Rev/Share 53.128
- Book/Share 30.4364
- PB 0.0887
- Debt/Equity 1.0436
- CurrentRatio 1.9253
- ROIC 0.0621
- MktCap 2040930.0
- FreeCF/Share -0.8001
- PFCF -0.0635
- PE 2.8776
- Debt/Assets 0.3979
- DivYield 0
- ROE 0.0602
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 2
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company's application to transfer the listing of its common stock to The Nasdaq Capital Market has been approved and the Company's securities will be transferred to The Nasdaq …
Read More
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Conduit regains compliance with Bid Price and Equity Requirements CDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announced that the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement (the “Bid Price Requirement”) set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq's stockholders' …
Read More
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-15 reverse stock split of the Company's common stock.
Read More
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla.
Read More
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit's pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. NAPLES, Fla.
Read More
Conduit Progresses Phase II of its AI Initiative with Sarborg
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Collaboration reinforces Conduit's commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug development Sarborg delivers a prototype AI-product to Conduit's Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the initial milestones in Phase II of its strategic collaboration with AI and Cybernetics company, Sarborg Limited.
Read More
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes. The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN).
Read More
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announces the repayment of its $600,000 promissory note (the “Note”) to Nirland Limited (“Nirland”) and provided an update on the conversion of its Senior Secured Promissory Note (the “Senior Note”) with Nirland.
Read More
About Conduit Pharmaceuticals Inc. (CDT)
- IPO Date 2022-03-28
- Website https://www.conduitpharma.com
- Industry Biotechnology
- CEO Dr. Andrew Regan
- Employees 6